Clinical Trials Logo

Type B Aortic Dissection clinical trials

View clinical trials related to Type B Aortic Dissection.

Filter by:
  • Recruiting  
  • Page 1

NCT ID: NCT06418828 Recruiting - Return to Work Clinical Trials

Patients With Type B Aortic Dissection Returning to Work After Dischargeļ¼ša Cross-sectional Survey

Start date: January 1, 2024
Phase:
Study type: Observational

This study wants to understand the incidence of returning to work after discharge in patients with type B aortic dissection.

NCT ID: NCT06087029 Recruiting - Clinical trials for Type B Aortic Dissection

IMPRoving Outcomes in Vascular DisEase- Aortic Dissection

IMPROVE-AD
Start date: April 14, 2024
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to determine whether an upfront invasive strategy of TEVAR plus medical therapy reduces the occurrence of a composite endpoint of all-cause death or major aortic complications compared to an upfront conservative strategy of medical therapy with surveillance for deterioration in patients with uncomplicated type B aortic dissection.

NCT ID: NCT05479305 Recruiting - Clinical trials for Type B Aortic Dissection

Evaluation of the Valiant Captivia Physician Fenestrated Stent Graft System in Aortic Arch and Descending Thoracic Aorta Pathologies

EVERGREEN
Start date: November 21, 2023
Phase: N/A
Study type: Interventional

The study objectives are to assess safety and effectiveness, measured acutely and at the 30-day visit after implantation of the Valiant Captivia physician fenestrated Stent Graft. Clinical utility measures throughout the procedure and until discharge will be assessed

NCT ID: NCT01984905 Recruiting - Clinical trials for Type B Aortic Dissection

Study of Prognostic Factors in Aortic Dissection Type B

TEDAC
Start date: October 2013
Phase: N/A
Study type: Observational

Clinical outcomes of chronic type B aortic dissections are unknown, especially in case of false lumen expansion and risk of rupture. Data of literature give us some indications about prognosis. The 1-year survival rate is about 80%, but we deplore the 25% rate of mortality at 3 years despite follow-up.The only known predictive factors are the initial diameter of more than 4 cm and the persistence of a false lumen patent.However, actual means of follow-up do not allow to predict severe complications. The aim of the sudy is to propose a diagnostic and preventive strategy for the follow-up of chronic type B aortic dissections treated medically. The primary objective is then to evaluate the prognostic role of 18-FDG-PET Scan in such patients in order to predict the risk of aortic diameter growth of more than 5 mm in 1 year and/or of an aortic dissections extension at 1 year. The secondary objectives are to evaluate the link between fibrosis biomarkers MMP et TIMP) and the results of imaging results (evolution of diameter and extension and results of PET-Scan imaging) Methods: 100 patients to be included in 3 years History of chronic type B aortic dissection, treated medically, evolving since more than 1 month and less than 5 years. Expected results: Prognostic contribution of 18FDG-PET-Scan and biomarkers for the identification of patients at high risk of evolution. Elaboration of a decisional algorithm about follow-up modalities of chronic aortic dissections. Demonstration of a correlation between aortic diameter growth or aortic dissection extension and intensity of marker fixation with 18-FDG-PET-Scan.